Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients.
Anna GiulianoBarbara KuterShari Pilon-ThomasJunmin WhitingQianxing MoBrett LeavBradley SirakChristopher CubittChristopher W DukesKimberly Isaacs-SorianoKayoko KennedySomedeb BallNing DongAkriti JainPatrick HwuJeffrey E LancetPublished in: Cancer communications (London, England) (2023)
Dose three of the mRNA-1273 vaccine was well-tolerated and augmented SARS-CoV-2 seropositivity in cancer patients, especially those who did not seroconvert post-dose two or whose GMTs significantly waned post-dose two. Lymphoid cancer patients experienced lower humoral responses to dose three of the mRNA-1273 vaccine, suggesting that timely access to boosters is important for this population.
Keyphrases